Cooley M&A

SEPTEMBER 16, 2022

There are compelling rationales for adopting a dual-class structure, but even proponents of the structure generally acknowledge that these benefits are significantly mitigated once the dual-class shares are out of the hands of the founders and/or pre-IPO stockholders. Voting agreements in public M&A transactions.

M&A 59

M&A IPO Shares Mergers and Acquisitions 59

The Deal

AUGUST 9, 2023

Our acquisition strategy is aligned with acquiring companies with a traditional product portfolio, who have success and marquee customer relationships that we can transform with our AI platform,” SymphonyAI CEO Sanjay Dhawan told The Deal. Following acquisitions, the company develops AI applications for the target’s clients.

M&A 40

M&A Private Equity Retail Financial Services 40

Focus Investment Banking

APRIL 14, 2024

Many smaller operators who are well positioned with a solid customer base, a robust portfolio of goods, and healthier product lines could explore a sale at today’s attractive pricing, with options to sell to an industry competitor or a private equity group (PEG).

M&A 52

M&A Food Private Equity Manufacturing 52

Growth Business

JULY 11, 2023

A management team will need to show they are ambitious, switched on and ready to push the boundaries in marketing, sales and finance. 3) Aquis Stock Exchange Aquis Stock Exchange , run by NEX, allows businesses to raise capital through Initial Public Offerings (IPOs). >See What is invoice factoring?

Finance 75

Finance Finance Business Funds 75

Mergers and Inquisitions

MAY 24, 2023

Here it is in the investor presentation: We don’t know the planned valuation for CMS in this spin-off, but let’s assume that Jacobs plans to spin it off at an IPO offering price that implies an 11.5x 5) Portfolio Concentration – Many special situations and distressed funds run concentrated portfolios (e.g.,

Funds 64

Funds Investors Mergers and Acquisitions Mergers 64

Chesapeake Corporate Advisors

AUGUST 16, 2024

When a PE firm purchases a business, the intent is to grow the company substantially (through organic growth and acquisitions) and quickly (usually within three to seven years) with the goal of a successful sale, to another PE firm, a strategic buyer, or through an Initial Public Offering (IPO).

Private Equity 52

Private Equity Equities Investment Business 52

Cooley M&A

JANUARY 25, 2023

For example, the sale of Horizon Therapeutics to Amgen for approximately $28 billion was the third-largest all-cash transaction in the pharmaceutical sector in history. Let’s dig in. It’s a more challenging market environment right now than we’ve seen in many years,” said Charlie Kim , who co-chairs Cooley’s capital markets practice.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Mergers and Inquisitions

JULY 31, 2024

Today, you could put most private equity activity in industrials into a few main categories: Consolidation / Roll-Up Plays – The idea is to acquire smaller companies to consolidate the parent company’s market position and become more appealing in an eventual IPO or M&A deal. Note that not all “large” funds do industrial deals.

Private Equity 66

Private Equity Equities Middle Market Debt 66

Mergers and Inquisitions

NOVEMBER 1, 2023

They do not invest in risky biotech startups attempting to cure cancer (at least not within their traditional PE portfolios). At the time of the deal, it was expected to grow sales at 3-5%: Remember that PE deals do not require “growth.” What about when the IPO market is shut down and exits look uncertain? in biology.

Private Equity 59

Private Equity Healthcare Equities Middle Market 59

Cooley M&A

JANUARY 23, 2024

Looming patent cliffs By 2030, more than 190 drugs will lose patent exclusivity , including 69 blockbuster drugs, putting at risk $236 billion in sales. Strategic innovation Strategic acquirers are feeling more pressure to consummate bolt-on acquisitions in order to round out their portfolios, enter new markets and fill innovation gaps.

M&A 52

M&A Mergers and Acquisitions Acquisitions Pharmaceutical 52

Cooley M&A

JANUARY 22, 2021

Divestitures, often achieved through asset sales, were also popular in 2020 as large pharmaceutical companies and biotechnology companies sought to divest noncore assets and focus on core businesses in the wake of economic uncertainty created by the pandemic. Life Sciences Enters the SPAC Party, But Will Reverse Merger Suitors Join In?

M&A 40

M&A Mergers and Acquisitions Collaboration Mergers 40

Cooley M&A

JANUARY 20, 2022

approved prescription cannabidiol medicine to its portfolio. In December, the Delaware Court of Chancery addressed another earnout dispute in a case arising from Auris Health’s 2019 sale to Johnson & Johnson for $5.75 stage R&D capabilities and expand its pipeline, and Jazz Pharma’s acquisition of GW Pharma for $7.2

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Mergers and Inquisitions

APRIL 10, 2024

3) Revenue Growth – Besides ticket and merchandise sales, sports teams can grow revenue with broadcast/licensing deals, partnerships, and newer routes like augmented reality (AR) / virtual reality (VR) experiences and e-gaming. But its sales were growing briskly, with 20 – 25% growth in the two previous years.

Private Equity 103

Private Equity Equities Funds Entertainment 103

Cooley M&A

FEBRUARY 1, 2024

Private equity slowed but not stopped by financing environment Despite record amounts of dry powder accumulating for sponsors, high financing costs, persistent valuation gaps and a closed tech IPO market led to a significant decrease in private equity M&A activity in 2023. Despite some isolated bright spots – such as Thoma Bravo’s $10.7

M&A 59

M&A Mergers and Acquisitions Private Equity Equities 59

Cooley M&A

JANUARY 25, 2023

Similarly, we expect sponsors to actively pursue carve out opportunities – like Francisco Partners’ carve out acquisition of the data and analytics assets from IBM’s Watson Health business – in 2023 as tech giants streamline their portfolios to focus on their core businesses.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Focus Investment Banking

NOVEMBER 18, 2024

If you are not aware of the fundamental private equity model, it is simple: buy (or invest in) a company, grow profits through increasing sales, cutting costs and/or add-on acquisitions, and then sell the larger, more profitable company for significantly more than it was purchased for.

Private Equity 52

Private Equity Equities IPO Valuation 52

Focus Investment Banking

FEBRUARY 11, 2025

Overcoming Marketplace Uncertainty Rising interest rates introduced a difficult environment for private equity recapitalizations (where private equity groups sell a portfolio company to another buyer), so few of the older PE-backed ophthalmology organizations traded hands over the last few years.

Private Equity 52

Private Equity Healthcare Equities Medical 52

Mergers and Inquisitions

MARCH 5, 2025

their Enterprise Values are not worth much for a long time): Hedge funds focusing on public biotech companies step into this process after the IPO part, which means they can bet on extreme value inflections based on binary outcomes. Short LQDA, Long UTHR: This works if you have the opposite view.

Funds 64

Funds Healthcare Mergers and Acquisitions Valuation 64

Mergers and Inquisitions

NOVEMBER 20, 2024

Communication/presentation skills and technical/modeling/deal skills are all quite important, but “sales skills” are also crucial if you’re interviewing at a firm with significant sourcing. Exits Up Slightly But Still Poor – M&A activity has ticked up modestly, but the IPO market is still mostly shut. Q: Why our firm/group?

Private Equity 59

Private Equity Equities Capital Valuation 59

Cooley M&A

JANUARY 22, 2025

By 2030, more than 190 commercial drugs will lose patent exclusivity , putting at risk $236 billion in Big Pharma sales. This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64

Cooley M&A

FEBRUARY 15, 2017

Dealmakers appear much more optimistic in the first quarter of 2017 than at this same time last year, in part because of greater optimism about the IPO market and the potential for favorable corporate tax and other regulatory changes. We expect this trend to continue, with mid-market and smaller deals driving the deal count in 2017.

M&A 40

M&A IPO Pharmaceutical Valuation 40